Ziprasidone

Drug Profile

Ziprasidone

Alternative Names: Captisol-enabled IV-Ziprasidone; CP 88059; CP 88059 01; CP-88059-1; Geodon; ME 2112; RQ-00000003; Zeldox; Ziprasidone hydrochloride; Ziprasidone mesylate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Meiji Seika Pharma; Pfizer; RaQualia Pharma
  • Class Antipsychotics; Piperazines; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia
  • No development reported Anxiety disorders
  • Discontinued Bipolar depression

Most Recent Events

  • 03 Aug 2017 Chemical structure information added
  • 21 Jun 2017 Ziprasidone is still in phase III trials for Bipolar disorders (In adolescents, In children) in USA (PO, Capsule) (NCT02075047)
  • 21 Jun 2017 Ziprasidone is still in phase III trials for Schizophrenia in Japan (PO, Capsule) (JapicCTI-152821),(JapicCTI-152822)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top